Greenleaf Trust Buys 2,279 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Greenleaf Trust boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,827 shares of the biopharmaceutical company's stock after purchasing an additional 2,279 shares during the quarter. Greenleaf Trust's holdings in Gilead Sciences were worth $3,230,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC increased its stake in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after buying an additional 2,450 shares during the period. Proficio Capital Partners LLC acquired a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $339,000. Personal CFO Solutions LLC acquired a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $207,000. Johnson Investment Counsel Inc. increased its stake in shares of Gilead Sciences by 10.3% in the fourth quarter. Johnson Investment Counsel Inc. now owns 16,629 shares of the biopharmaceutical company's stock valued at $1,536,000 after buying an additional 1,549 shares during the period. Finally, Independent Advisor Alliance increased its stake in shares of Gilead Sciences by 35.4% in the fourth quarter. Independent Advisor Alliance now owns 32,128 shares of the biopharmaceutical company's stock valued at $2,968,000 after buying an additional 8,398 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total transaction of $330,510.00. Following the completion of the sale, the insider owned 120,168 shares in the company, valued at approximately $13,238,908.56. This trade represents a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction that occurred on Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the transaction, the chief executive officer directly owned 615,725 shares of the company's stock, valued at approximately $68,006,826.25. The trade was a 1.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 58,500 shares of company stock worth $6,340,745. 0.27% of the stock is owned by corporate insiders.

Analyst Ratings Changes

GILD has been the topic of several analyst reports. Cantor Fitzgerald initiated coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. Morgan Stanley upped their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Finally, Oppenheimer dropped their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average price target of $111.38.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded down $4.67 during midday trading on Friday, reaching $109.87. 3,052,960 shares of the company's stock traded hands, compared to its average volume of 7,688,470. The company has a market cap of $136.68 billion, a price-to-earnings ratio of 23.15, a P/E/G ratio of 0.73 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. Gilead Sciences, Inc. has a one year low of $68.14 and a one year high of $119.96. The stock has a 50 day moving average of $107.62 and a 200 day moving average of $104.50.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. Gilead Sciences's revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.32) earnings per share. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.88%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's payout ratio is 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.